In avapritinib-treated GIST, rapid objective responses in PDGFRA D842V-mutant tumors serve as predictive biomarkers for durable disease control, reinforcing the role of early genomic and phenotypic assessment in guiding therapy [194]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.